J. Goldman & CO LP Aeterna Zentaris Inc. Transaction History

J. Goldman & CO LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$1.0 - $2.97 $20,000 - $59,400	-20,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$2.04 - $5.43 $722,160 - $1.92 Million	-354,000 Reduced 94.65%	20,000 $59,000
Q1 2019 May 14, 2019	SELL	$3.03 - $4.65 $1.89 Million - $2.9 Million	-623,494 Reduced 62.51%	374,000 $1.74 Million
Q4 2018 Feb 14, 2019	BUY	$1.3 - $3.87 $1.3 Million - $3.86 Million	997,494 New	997,494 $2.93 Million

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.